About Ferrosan Medical Devices

Since 1947 Ferrosan Medical Devices has developed and manufactured hemostatic products, used by clinical professionals to stop bleedings during operations in hospitals.

The company’s innovative products, including the flagship gelatine-based hemostatic agents, address critical bleeding management needs in surgery, contributing significantly to patient outcomes and operating room efficiency. The products are sold in partnership with Ethicon (Johnson & Johnson) in more than 100 countries.

Every two seconds a device from Ferrosan Medical Devices is used somewhere in the world.

Revenue
DKKm

2019
528
2020
622
2021
704
2022
810
2023
893

Why did we invest in Ferrosan Medical Devices?

Kirk Kapital first invested in Ferrosan Medical Devices in 2016, alongside private equity firm Impilo. In 2022, Kirk Kapital established a consortium consisting of the Lundbeck Foundation and ATP to acquire the entire company. At the same time, we increased our ownership stake from 30% to 40%.

Our increased stake reflects our commitment to supporting Ferrosan Medical Devices’ growth and innovation in the healthcare sector. This partnership aligns with Kirk Kapital’s strategy to invest in businesses that make a positive impact and demonstrate strong potential for long-term value creation.
As healthcare systems worldwide become more developed, the number of patients undergoing surgery increases, thereby raising the demand for Ferrosan Medical Devices’ products.

Kirk Kapital’s flexible ownership horizon enables Ferrosan Medical Devices to continuously invest in new product development and operational excellence, supporting the company’s competitive position over the years to come.

Value creation initiatives

Production & Quality excellence

Ensure constant ability to release high-quality products

Product innovation

Develop new innovative medical devices to enable better surgical care

Strategic partnerships

Enhance and develop strategic partnerships with commercial partners

Learn more

Kirk Kapital increases ownership stake in Ferrosan Medical Devices from 30 per cent to 40 per cent

27.09.2022
Read article

Contact person

Kim Gulstad
Send email